CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Operating activities:
Net income	$ 3,720	$ 5,322
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	1,212	1,005
Amortization of intangibles	6,036	1,485
Impairment of intangibles	7,402
Gain on sale of investments and fixed assets	(2,583)	(10)
Stock-based compensation expense	2,460	2,313
Other than temporary decline in value of investments	524
Change in valuation of deferred acquisition consideration	206	327
Change in valuation of warrant liability	129	(133)
Recognition of gain on disposition of assets and sale of products	(1,276)	(700)
Changes in operating assets and liabilities:
Accounts receivable	4,539	2,998
Income tax receivable	(3,075)	(954)
Prepaid expenses and other assets	117	408
Restricted cash		2,134
Accounts payable and other accrued liabilities	(2,623)	(1,335)
Deferred tax liability	(5,771)	(1,272)
Deferred revenue	(1,430)	(562)
Net cash provided by operating activities	9,587	11,026
Investing activities:
Purchases of marketable securities	(132,329)	(57,717)
Sales and maturities of marketable securities	120,987	59,713
Proceeds from sale of products	700	700
Purchases of property and equipment	(872)	(629)
Proceeds from sale of property and equipment		37
Acquisition of Astex Therapeutics net assets, net of cash acquired		(269)
Payment of deferred consideration relating to acquisition of Astex Therapeutics Limited	(12,272)
Net cash provided by (used in) investing activities	(23,786)	1,835
Financing activities:
Proceeds from issuances of common stock	606	251
Net cash provided by financing activities	606	251
Effect of foreign exchange rate changes on cash and cash equivalents	577	(727)
Net increase (decrease) in cash and cash equivalents	(13,016)	12,385
Cash and cash equivalents at beginning of period	39,788	25,554
Cash and cash equivalents at end of period	26,772	37,939
Supplemental Disclosure of Non-Cash Investing Activities:
Fixed assets and intellectual property transferred in exchange for investment	924
Common stock issued in connection with Astex Therapeutics acquisition		95,119
Fair value of stock options assumed in connection with Astex Therapeutics acquisition		3,270
Fair value of warrants assumed in connection with Astex Therapeutics acquisition		301
Supplemental Disclosure of Cash Flow Information:
Income taxes paid in cash during the period		$ 39